Description
We are evaluating the effects of treatment of patients with MHE with rifaximin on neurological, cerebral, immunological, metabolic and exosome alterations. Line funded by the ISCIII (PI18/00150).
Keywords
fatty liver disease, steatohepatitis, cognitive impairment, biomarkers, inflammation, immunophenotyping, magnetic resonance imaging
Manager UV
- Montoliu Felix, Maria Del Carmen
- PDI-Catedratic/a d'Universitat
Frascati classification
